

United Guardian Inc. (UG)

Nasdaq; chemicals; SIC 2844, Perfumes, Cosmetics & Other Toilet Preparations; CIK 0000101295

United Guardian Inc. UG; chemicals	
Grade	A/B A B C D E on the A/B boundary of 331 graded peers percentile 22.1; sampling error 2.7 points; lower is stronger
Rank	66 of 331
Profitability	C percentile 56.2
Solvency	A percentile 3.5
Growth and financing	D percentile 62.9
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$13.1M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: fortress balance sheet
Inputs computable	11 of 14
Graded from	filings received through Mar 27, 2026 196 days before the rescans; latest periodic filing 10-Q received Aug 11, 2026
Last close	\$7.13 2026-10-06; market equity \$32.8M
Price used in grade	None



A/B, the bull
on the A/B boundary of its sector; letters are fifths of the 331 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: B from Sep 26, 2026, A/B from Oct 3, 2026, B from Oct 6, 2026, A/B from Oct 7, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

United-Guardian, Inc. ("Company") is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients and a line of healthcare products including pharmaceuticals and medical lubricants. We conduct various research and development ("R&D") activities. Our R&D department primarily develops new and unique specialty cosmetic and sexual wellness ingredients. We develop new products using natural and

environmentally friendly raw materials, which is a priority for many of our cosmetic customers.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 56.2						
Gross profitability		39.2%	21.3%	11.7	359	2025-12-31
Return on invested capital		not computable	9.5%			one or more required annual facts are missing
Accruals ratio		1.0%	(4.2%)	85.2	400	2025-12-31
Gross margin stability, five years		3.5 pts	2.2 pts	71.7	301	2025-12-31
Solvency, sleeve percentile 3.5						
Twelve-month failure probability		0.01%	0.05%	0.0	40	2026-06-30
Altman Z double-prime		15.38	3.41	3.3	301	2025-12-31
Net debt to EBITDA		not computable	1.88x			one or more required annual facts are missing
Interest coverage		not computable	4.16x			one or more required annual facts are missing
Current ratio		7.31x	2.20x	7.1	423	2025-12-31
Growth and financing, sleeve percentile 62.9						
Revenue growth, three-year compound		(6.0%)	1.2%	80.8	350	2025-12-31
Free cash flow growth, three-year compound		(8.0%)	12.6%	81.5	179	2025-12-31
Reinvestment rate		(15.0%)	24.3%	74.0	170	2025-12-31
Asset growth, three years		7.2%	2.9%	30.2	369	2025-12-31
Net share issuance, one year		0.0%	0.0%	48.3	321	2026-03-01

Among 331 peers

chemicals; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
61	Taylor Devices, Inc. (TAYD)	20.9	A/B	
62	Church & Dwight Co. Inc. (CHD)	20.9	A/B	
63	Ilex Corp. (IEX)	21.3	A/B	
64	Curtiss Wright Corp. (CW)	21.7	A/B	
65	Donaldson Co. Inc. (DCI)	22.0	A/B	
66	United Guardian Inc. (UG) <	22.1	A/B	
67	Quanex Building Products Corp. (NX)	22.4	A/B	
68	REX American Resources Corp. (REX)	22.7	B	fortress balance sheet
69	Middleby Corp. (MIDD)	22.8	A/B	

70	Valmont Industries Inc. (VMI)	23.2	B
71	AAR Corp. (AIR)	23.6	B

What the price implies

at the 2026-10-06 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(0.9%)	13.8%	33
Distance from 52-week high	(13.3%)	(24.2%)	75
EBIT to enterprise value	not computable	3.9%	
Free cash flow yield	5.8%	3.2%	77
Book value to price	0.36	0.39	48
Sales to price	0.32	0.57	29
Composite equity issuance, five years	(31.5%)	(9.9%)	11
Relative strength against the sector, log excess return	(0.18)	(0.02)	30

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$2.4M
Operating cash flow, four quarters	\$3.5M
Months of runway	not finite
Days since last periodic filing	59 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	\$51,266

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$10.5M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$5.4M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
3	assets	us-gaap:Assets	\$13.1M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
4	net income	us-gaap:NetIncomeLoss	\$2.1M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.0M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
6	assets	us-gaap:Assets	\$13.8M	2024-12-31	2026-03-27	10-K	0001171843-26-001973
7	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$12.2M	2024-12-31	2026-03-27	10-K	0001171843-26-001973
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$5.7M	2024-12-31	2026-03-27	10-K	0001171843-26-001973
9	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$10.9M	2023-12-31	2025-03-21	10-K	0001171843-25-001611
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$5.5M	2023-12-31	2025-03-21	10-K	0001171843-25-001611
11	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$12.7M	2022-12-31	2024-03-22	10-K	0001171843-24-001526
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$6.0M	2022-12-31	2024-03-22	10-K	0001171843-24-001526
13	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$13.9M	2021-12-31	2023-03-23	10-K	0001171843-23-001846
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$5.7M	2021-12-31	2023-03-23	10-K	0001171843-23-001846
15	current assets	us-gaap:AssetsCurrent	\$12.2M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
16	current liabilities	us-gaap:LiabilitiesCurrent	\$1.7M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$10.8M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
18	operating income	us-gaap:OperatingIncomeLoss	\$2.2M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
19	book equity	us-gaap:StockholdersEquity	\$11.2M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
20	liabilities	us-gaap:Liabilities	\$1.9M	2025-12-31	2026-03-27	10-K	0001171843-26-001973

21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$58,995	2025-12-31	2026-03-27	10-K	0001171843-26-001973
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.5M	2024-12-31	2026-03-27	10-K	0001171843-26-001973
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$433,077	2024-12-31	2026-03-27	10-K	0001171843-26-001973
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.1M	2023-12-31	2025-03-21	10-K	0001171843-25-001611
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$165,716	2023-12-31	2025-03-21	10-K	0001171843-25-001611
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.5M	2022-12-31	2024-03-22	10-K	0001171843-24-001526
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$75,179	2022-12-31	2024-03-22	10-K	0001171843-24-001526
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$108,200	2025-12-31	2026-03-27	10-K	0001171843-26-001973
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$2.6M	2025-12-31	2026-03-27	10-K	0001171843-26-001973
30	income tax	us-gaap:IncomeTaxExpenseBenefit	\$537,277	2025-12-31	2026-03-27	10-K	0001171843-26-001973
31	current assets	us-gaap:AssetsCurrent	\$12.7M	2024-12-31	2026-03-27	10-K	0001171843-26-001973
32	current liabilities	us-gaap:LiabilitiesCurrent	\$1.9M	2024-12-31	2026-03-27	10-K	0001171843-26-001973
33	assets	us-gaap:Assets	\$12.9M	2023-12-31	2025-03-21	10-K	0001171843-25-001611
34	assets	us-gaap:Assets	\$10.6M	2022-12-31	2024-03-22	10-K	0001171843-24-001526
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,594,319	2026-03-01	2026-03-27	10-K	0001171843-26-001973
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,594,319	2025-03-01	2025-03-21	10-K	0001171843-25-001611